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HIV/AIDS

Rachel Muir, BSN, RN
O1erbein University, Westerville, Ohio
Introduc0on
Human Immunodeﬁciency Virus (HIV) is a disease in which the virus a8acks and
depletes the CD4+ T cells leading to a weakened immune system in which a paBent can
no longer ﬁght pathogens. This weakening of the paBent’s immune system makes them
more suscepBble to opportunisBc infecBons and malignancies (Coﬃn & Swanstrom,
2017). In the iniBal acute HIV infecBon period the paBent usually does not show
symptoms but is highly infecBous which can allow for transmission unknowingly
(Center for Disease Control and PrevenBon, 2017). HIV can eventually progress to AIDS
without treatment.
Admission to the hospital can expose this paBent to many opportunisBc pathogens and
complicate treatment plan.
In Columbus, Ohio, at Grant Medical Center there is a need for be8er understanding of
HIV and the impact it can potenBally have on paBents who are acutely ill in the criBcal
care seUng which is why this topic was chosen.

Underlying Pathophysiology

HIV is a virus which is a member of the lenBvirus genus, part of the retroviridae family
(Moss, 2013). The characterisBcs of this family of viruses are long latency periods and
progressive infecBon allowing the virus to invade the hosts immune response (Moss,
2013). On the surface of the HIV are two anBgens, glycoproteins 120 and 41 (gp120
and gp 41) which allow the virus to bind with the target cell using CXCR4 and CCR5 as
co-receptors. CCR5 is expressed on memory cells where CXCR4 is expressed on
memory and naïve CD4 T cells (Swanstrom & Coﬃn, 2013). HIV starts with the
infecBon of a single CD4 T cell. Once in the cell, RNA is released in the cytoplasm of
the cell. Using the host’s nucleoBdes, HIV enzyme reverse transcriptase transforms
the viral RNA into single-stranded DNA. As this occurs, errors are made due to poor
“proofreading” and single stranded DNA is reverse-transcribed and synthesized as
double-stranded DNA. The double stranded DNA is then carried to the nucleus and
inserts it into the hosts chromosome. (Moss, 2013). HIV conBnues to replicate in CD4
T cells and as a new viron is formed cell death occurs to the host allowing the virus to
be released to infect other CD4 cells (Swanstrom & Coﬃn, 2013). As the virus
replicates there is a signiﬁcant decrease in CD4 T cells over Bme leading to
immunodeﬁciency; leaving the host suscepBble to infecBons and malignancies (Moss,
2013).

Signiﬁcance of Pathophysiology
• Transmission of the HIV virus occurs from and infected
person by blood, semen and vaginal ﬂuids through means
such as needlesBcks, intravenous drug use, sexual
intercourse, blood products or mother-to-child.
•Up to 80% of transmission in adults is through sexual
intercourse (Moss, 2013). Early diagnosis and treatment is
key to prevent further transmission and control of the
disease progression. Most HIV viruses can be detected
within 25-30 days (Moss, 2013)
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HIV Diagnosis & Treatment
Three types of tests are available to detect and diagnose HIV. They are anBbody tests,
combinaBon or fourth-generaBon tests, and nucleic acid tests (NATs).
An0body detec0on tests: ELISA is a test in which HIV anBgens are used to detect
anBbodies in the paBent’s blood serum. The CDC recommends conﬁrmaBon of the
posiBve result of the ELISA test using Western blot test. The Western blot test is able to
idenBfy anBbodies of a speciﬁc molecular weight, eliminaBng false posiBve results
(Moss, 2013).
Combina0on or fourth-genera0on tests: These tests are looking for both anBgens and
anBbodies
which can be detected 2 to 6 weeks amer infecBon (Center for Disease Control and
PrevenBon, 2017)
Nucleic acid tests: This test is the fastest, it is able to detect the virus in the blood amer
7 to 28 days.
This test is typically not used due to the high cost (CDC, 2017).
Treatment: Once a diagnosis has been made, early treatment is imperaBve. Although
there is currently no cure for HIV, the use of highly acBve anBretroviral therapy (HAART)
has decreased morbidity and mortality to those diagnosed with HIV. These drugs
decrease the viral load which slows the progression of the disease as well as decreasing
the risk of transmission. (Moss, 2013). The progression of anBretroviral therapy has
make this once deadly disease into a manageable chronic disease (Sweet, AlBce, Cohen
& Vandewalle, 2016).

Implica0ons for Nursing Care
•EducaBon to those who are at high risk for
contracBng this disease is important. HIV is more
common among ethnic/racial minoriBes,
homosexual and bisexual men, and intravenous
drug users (Moss, 2013).
•To decrease transmission among high risk groups
educaBon such as safe sex pracBce using condoms,
using clean needles for intravenous drug use as well
as importance of tesBng are all crucial.
•Under the Aﬀordable Care Act, HIV screening is
covered without co-pay to those who have health
insurance and many other resources are available
for those who are not covered by health insurance.
• Once a paBent has contracted HIV, early start of
anBretroviral therapy (ART) is important. There are
many federal and state resource available for those
who are not covered by insurance to help pay for
ART therapy (HIV.gov, 2017).
.

Signs & Symptoms

The HIV infecBon occurs in four stages:
Stage 1- During the primary infecBon, which lasts for a few weeks, the person may or
may not have symptoms. Symptoms present are usually ﬂu-like such as fever,
headache, muscle ache, rash and joint pain (HIV.gov, 2017). During this stage there is
a signiﬁcant amount of HIV circulaBng and the immune system is responding by
generaBng anBbodies, a process called seroconversion, allowing the paBents to test
posiBve when tests are conducted for anBbodies (Moss, 2013)
Stage 2- During the clinically asymptomaBc stage most symptoms are absent with the
excepBon of swollen glands. Although the paBent may not have symptoms, the
individual is sBll infecBous (Moss, 2013). This stage can last on average ten years
without anBretroviral therapy, and for much longer in those receiving anBretroviral
therapy (HIV.gov, 2017).
Stage 3- Following the asymptomaBc stage, HIV becomes symptomaBc when the CD4
lymphocyte count drops below 200 cells/uL. As the immune system is weakened due
to damage of Bssues and lymph nodes, viral mutaBon and further destrucBon of T
cells, the person becomes more suscepBble to opportunisBc infecBons and
malignancies (Moss, 2013). Symptoms at this Bme can include: rapid weight loss,
night sweats, diarrhea, pneumonia, red, brown, pink or purple blotches on skin and
memory loss or other neurologic disorders (HIV.gov, 2017). As the person progresses
to AIDS, they are more likely to be suscepBble to more severe infecBons and cancers.
Examples are Hodgkin disease, squamous cell carcinoma and severe
lymphadenopathy (Moss, 2013).
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Conclusion
As more research is done and innovaBons conBnue,
the hope is to eventually eradicate the HIV virus. At
this Bme vaccine trials have not been eﬀecBve. Yet,
as we understand more about the global geneBc
variaBons and their speciﬁc pathogenic potenBal
reducing new infecBons and ﬁnding a cure is
becoming more of a reality. These breakthroughs
allowed The United States, in 2010, to develop a
plan to address AIDS by decreasing these new
infecBons, increasing access to care and improving
the outcomes to those with HIV (Kla8, Chomont,
Douek & Deeks, 2013).
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